Keyword: Ninlaro

In a phase 3 trial of Ninlaro as a first-line maintenance treatment in multiple myeloma, patients experienced significant survival benefits.

Takeda's working to grow Ninlaro into a blockbuster, but the drug failed a phase 3 test in systemic light-chain AL amyloidosis, crimping hopes for a new indication.

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.

Takeda withdrew an FDA filing for Ninlaro in post-transplant maintenance because it doesn't yet have survival data the agency wants.

The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.

Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.